Compare PCRX & CGBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCRX | CGBD |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | United States |
| Employees | N/A | 2500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 772.5M |
| IPO Year | 2010 | N/A |
| Metric | PCRX | CGBD |
|---|---|---|
| Price | $23.78 | $11.40 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 8 |
| Target Price | ★ $30.25 | $12.92 |
| AVG Volume (30 Days) | 518.7K | ★ 751.8K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 14.92% |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $541,533,000.00 | N/A |
| Revenue This Year | $6.78 | $3.74 |
| Revenue Next Year | $8.54 | $1.80 |
| P/E Ratio | $150.19 | ★ $10.36 |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $10.64 |
| 52 Week High | $27.99 | $15.15 |
| Indicator | PCRX | CGBD |
|---|---|---|
| Relative Strength Index (RSI) | 57.59 | 56.56 |
| Support Level | $23.74 | $10.64 |
| Resistance Level | $23.94 | $11.44 |
| Average True Range (ATR) | 0.73 | 0.28 |
| MACD | 0.11 | 0.05 |
| Stochastic Oscillator | 75.36 | 94.72 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.